Tacrolimus inhibits T-lymphocyte activation, although the exact mechanism of action unclear. Tacrolimus bind to cytosolic receptors known as immunophilins (i.e., cyclophilin and FK binding protein-12 [FKBP-12], respectively), forming complexes that inhibit the production of cytokines via the calcineurin pathway. Inhibition of calcineurin activity inhibits early activation of T-cells (ie.immunosuppresion results).
(in Tablet form)
Pharyngitis/Tonsillitis: 250 mg for 10 days
Acute maxillary sinusitis: 500 mg for 14 days
Chronic bronchitis: 250 – 500 mg for 7-14 days
Pneumonia: 250 mg for 7-14 days
Uncomplicated skin and skin structure infections: 250 mg for 7-14 days
Community-acquired upper and lower respiratory tract infections: 250 – 500 mg for 5-14 days
Body weight under 8 kg: 7.5 mg/kg twice daily
Body weight of 8-11 kg (1-2 years): 62.5 mg twice daily
Body weight of 12-19 kg (3-6 years): 125 mg twice daily
Body weight of 20-29 kg (7-9 years): 187.5 mg twice daily
Body weight of 30-40 kg (10-12 years): 250 mg twice daily
Manufacturer: Square Pharmaceutical Ltd.